Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

VRDN-008 is a half-life extended bispecific FcRn inhibitor comprising an Fc fragment and an albumin-binding domain designed to prolong IgG suppression and provide a potentially best-in-class ...

Albumin binding to FcRn, GP60, and SPARC results in an improved PK profile, decreased toxicity risk, and a broader therapeutic index preclinically, with significant targeting of the tumor ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...

The one notable exception to that is some anti FcR antibodies also interfere with the binding of albumin to FcRn, to the receptor. And that results in a lowering of blood albumin levels.

The one notable exception to that is some anti FcR antibodies also interfere with the binding of albumin to FcRn, to the receptor. And that results in a lowering of blood albumin levels. And that has ...

There were no clinically significant increases in ALT/AST or bilirubin, no clinically significant reductions in albumin and no clinically ... antibodies targeting FcRn inhibition, offering a ...

Nipocalimab binds FcRn with high specificity ... By modulating IgG levels without impacting albumin recycling or broader immune function, nipocalimab presents a targeted strategy for potentially ...

VRDN-008 is a half-life extended bispecific FcRn inhibitor comprising an Fc fragment and an albumin-binding domain designed to prolong IgG suppression and provide a potentially best-in-class ...